Who are Deaminooxytocin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oxytocin 5 Usp Units In Dextrose 5%, Carbetocin bolus, Oxytocin 2 mIU/mL, Oxytocin (High dose), Carbetocin infusion, Oxytocin versus oxytocin-ergometrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/demoxytocin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Deaminooxytocin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deaminooxytocin (DEMOXYTOCIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: demoxytocin. Area: Neuroscience.

phase 2 demoxytocin Oxytocin receptor Neuroscience Recombinant protein Live · refreshed every 30 min

Target snapshot

Deaminooxytocin (DEMOXYTOCIN). Deaminooxytocin is thought to work by mimicking the action of oxytocin, a hormone involved in social bonding and childbirth, but with a modified structure that allows it to be a small molecule.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Deaminooxytocin TARGET	DEMOXYTOCIN		phase 2	demoxytocin	Oxytocin receptor
Oxytocin 5 Usp Units In Dextrose 5%	OXYTOCIN	Fresenius Kabi	marketed	Adrenocorticotropic Hormone [EPC]	Oxytocin receptor	1980-01-01
Carbetocin bolus	Carbetocin bolus	Ciusss de L'Est de l'Île de Montréal	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)
Oxytocin 2 mIU/mL	Oxytocin 2 mIU/mL	Assistance Publique - Hôpitaux de Paris	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)
Oxytocin (High dose)	Oxytocin (High dose)	The University of Texas Medical Branch, Galveston	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)
Carbetocin infusion	Carbetocin infusion	Ciusss de L'Est de l'Île de Montréal	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)
Oxytocin versus oxytocin-ergometrine	Oxytocin versus oxytocin-ergometrine	Hadassah Medical Organization	marketed	Uterotonic agent	Oxytocin receptor (OXTR); ergometrine acts on alpha-adrenergic and serotonin receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (demoxytocin class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Deaminooxytocin — Competitive Intelligence Brief. https://druglandscape.com/ci/demoxytocin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing